Mineralys Therapeutics, Inc. MLYS Purchases of fixed maturity securities
Purchases of fixed maturity securities at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireHeldToMaturitySecurities.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s purchases of fixed maturity securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s purchases of fixed maturity securities?
- Mineralys Therapeutics, Inc. (MLYS) reported purchases of fixed maturity securities of $347.44M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s purchases of fixed maturity securities changed year-over-year?
- Mineralys Therapeutics, Inc.'s purchases of fixed maturity securities increased by 171.7% year-over-year, from $127.88M to $347.44M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s purchases of fixed maturity securities?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s purchases of fixed maturity securities has grown at a 124.8% compound annual growth rate (CAGR), from $71.76M to $814.74M.
- What does purchases of fixed maturity securities mean?
- Cash spent purchasing fixed-income securities (bonds, notes, debentures) for the investment portfolio.